Your browser doesn't support javascript.
loading
Radical Cystectomy Against Intravesical BCG for High-Risk High-Grade Nonmuscle Invasive Bladder Cancer: Results From the Randomized Controlled BRAVO-Feasibility Study.
Catto, James W F; Gordon, Kathryn; Collinson, Michelle; Poad, Heather; Twiddy, Maureen; Johnson, Mark; Jain, Sunjay; Chahal, Rohit; Simms, Matt; Dooldeniya, Mohantha; Bell, Richard; Koenig, Phillip; Conroy, Samantha; Goodwin, Louise; Noon, Aidan P; Croft, Julie; Brown, Julia M.
Afiliação
  • Catto JWF; Academic Urology Unit, University of Sheffield, Sheffield, United Kingdom.
  • Gordon K; Clinical Trials Research Unit, Leeds Institute for Clinical Trials Research, University of Leeds, Leeds, United Kingdom.
  • Collinson M; Clinical Trials Research Unit, Leeds Institute for Clinical Trials Research, University of Leeds, Leeds, United Kingdom.
  • Poad H; Clinical Trials Research Unit, Leeds Institute for Clinical Trials Research, University of Leeds, Leeds, United Kingdom.
  • Twiddy M; Institute of Clinical and Applied Health Research, University of Hull, Hull, United Kingdom.
  • Johnson M; Freeman Hospital, Newcastle, United Kingdom.
  • Jain S; St James's University Hospital, Leeds, United Kingdom.
  • Chahal R; Bradford Teaching Hospitals NHS Foundation Trust, Bradford, United Kingdom.
  • Simms M; Hull and East Yorkshire NHS Trust, Hull, United Kingdom.
  • Dooldeniya M; Mid Yorkshire Hospitals NHS Trust, Wakefield, United Kingdom.
  • Bell R; Churchill Hospital, Oxford University Hospitals NHS Trust, Oxford, United Kingdom.
  • Koenig P; Airedale NHS Foundation Trust, Keighley, United Kingdom.
  • Conroy S; Academic Urology Unit, University of Sheffield, Sheffield, United Kingdom.
  • Goodwin L; Academic Urology Unit, University of Sheffield, Sheffield, United Kingdom.
  • Noon AP; Department of Urology, Royal Hallamshire Hospital, Sheffield, United Kingdom.
  • Croft J; Clinical Trials Research Unit, Leeds Institute for Clinical Trials Research, University of Leeds, Leeds, United Kingdom.
  • Brown JM; Clinical Trials Research Unit, Leeds Institute for Clinical Trials Research, University of Leeds, Leeds, United Kingdom.
J Clin Oncol ; 39(3): 202-214, 2021 01 20.
Article em En | MEDLINE | ID: mdl-33332191
ABSTRACT

PURPOSE:

High-grade nonmuscle invasive bladder cancer (HRNMIBC) is a heterogeneous disease. Treatments include intravesical maintenance Bacillus Calmette-Guerin (mBCG) and radical cystectomy (RC). We wanted to understand whether a randomized trial comparing these options was possible. MATERIALS AND

METHODS:

We conducted a two-arm, prospective multicenter randomized study to determine the feasibility in Bacillus Calmette-Guerin-naive patients. Participants had new high-risk HRNMIBC suitable for both treatments. Random assignment was stratified by age, sex, center, stage, presence of carcinoma in situ, and prior low-risk bladder cancer. Qualitative work investigated how to maintain equipoise. The primary outcome was the number of patients screened, eligible, recruited, and randomly assigned.

RESULTS:

We screened 407 patients, approached 185, and obtained consent from 51 (27.6%) patients. Of these, one did not proceed and therefore 50 were randomly assigned (11). In the mBCG arm, 23/25 (92.0%) patients received mBCG, four had nonmuscle invasive bladder cancer (NMIBC) after induction, three had NMIBC at 4 months, and four received RC. At closure, two patients had metastatic BC. In the RC arm, 20 (80.0%) participants received cystectomy, including five (25.0%) with no tumor, 13 (65.0%) with HRNMIBC, and two (10.0%) with muscle invasion in their specimen. At follow-up, all patients in the RC arm were free of disease. Adverse events were mostly mild and equally distributed (15/23 [65.2%] patients with mBCG and 13/20 [65.0%] patients with RC). The quality of life (QOL) of both arms was broadly similar at 12 months.

CONCLUSION:

A randomized controlled trial comparing mBCG and RC will be challenging to recruit into. Around 10% of patients with high-risk HRNMIBC have a lethal disease and may be better treated by primary radical treatment. Conversely, many are suitable for bladder preservation and may maintain their prediagnosis QOL.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Vacina BCG / Cistectomia / Antineoplásicos Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Qualitative_research / Risk_factors_studies Aspecto: Patient_preference Limite: Female / Humans / Male País/Região como assunto: Europa Idioma: En Revista: J Clin Oncol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Vacina BCG / Cistectomia / Antineoplásicos Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Qualitative_research / Risk_factors_studies Aspecto: Patient_preference Limite: Female / Humans / Male País/Região como assunto: Europa Idioma: En Revista: J Clin Oncol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido